Media coverage about Pro-Dex (NASDAQ:PDEX) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pro-Dex earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 48.893419761585 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of NASDAQ:PDEX traded down $0.25 on Friday, hitting $9.75. The stock had a trading volume of 32,191 shares, compared to its average volume of 24,360. Pro-Dex has a twelve month low of $6.05 and a twelve month high of $11.00. The company has a market capitalization of $43.53 million, a PE ratio of 19.23 and a beta of -0.20.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, August 30th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.16. Pro-Dex had a net margin of 9.94% and a return on equity of 13.54%.

Pro-Dex Company Profile

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and machined parts.

Featured Article: Understanding Analyst Recommendations

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.